1 Min Read
Feb 28 (Reuters) - Biocryst Pharmaceuticals Inc:
* BIOCRYST ANNOUNCES INITIATION OF THE APEX-S LONG-TERM SAFETY TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.